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Background: Colorectal cancer (CRC) is a heterogeneous and biologically poorly understood disease. To tailor CRC
treatment, it is essential to first model this heterogeneity by defining subtypes of patients with homogeneous
biological and clinical characteristics and second match these subtypes to cell lines for which extensive
pharmacological data is available, thus linking targeted therapies to patients most likely to respond to treatment.
Methods: We applied a new unsupervised, iterative approach to stratify CRC tumor samples into subtypes based
on genome-wide mRNA expression data. By applying this stratification to several CRC cell line panels and
integrating pharmacological response data, we generated hypotheses regarding the targeted treatment of different
subtypes.
Results: In agreement with earlier studies, the two dominant CRC subtypes are highly correlated with a gene
expression signature of epithelial-mesenchymal-transition (EMT). Notably, further dividing these two subtypes using
iNMF (iterative Non-negative Matrix Factorization) revealed five subtypes that exhibit activation of specific signaling
pathways, and show significant differences in clinical and molecular characteristics. Importantly, we were able to
validate the stratification on independent, published datasets comprising over 1600 samples. Application of this
stratification to four CRC cell line panels comprising 74 different cell lines, showed that the tumor subtypes are well
represented in available CRC cell line panels. Pharmacological response data for targeted inhibitors of SRC, WNT,
GSK3b, aurora kinase, PI3 kinase, and mTOR, showed significant differences in sensitivity across cell lines assigned to
different subtypes. Importantly, some of these differences in sensitivity were in concordance with high expression
of the targets or activation of the corresponding pathways in primary tumor samples of the same subtype.
Conclusions: The stratification presented here is robust, captures important features of CRC, and offers valuable
insight into functional differences between CRC subtypes. By matching the identified subtypes to cell line panels
that have been pharmacologically characterized, it opens up new possibilities for the development and application
of targeted therapies for defined CRC patient sub-populations.
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Colorectal cancer (CRC) is the third most common
cancer, with an estimated 1.2 million cases and 608,700
deaths worldwide in 2008 [1]. While the overall effects
and interactions of environmental and lifestyle factors
[2], and inherited and acquired genetic and epigenetic
alterations [3-5] on CRC development are still incom-
pletely understood, knowledge has improved in recent
years.
The generally assumed model of CRC development
implies a sequence of events leading from adenoma for-
mation to carcinoma that is caused and accompanied by
genetic and epigenetic events [3]. Different molecular
phenotypes have been used to define CRC subtypes
[6,7], for instance microsatellite instability (MSI) [8],
epigenetic alterations, such as the methylation state of
CpG islands [9], the location of the tumor in the colon/
rectum, and mutations in genes, such as KRAS or
BRAF. Key pathways that have been implicated in CRC
include Wnt/ß-catenin, TGF-ß, MAPK, and PI3K sig-
naling [3].
Intense research has been directed at the discovery of
biomarkers that are predictive of disease progression or
treatment response, albeit with limited success. For
Stage II and III CRC, microsatellite instability was found
to be predictive of better prognosis [6]. Tumor staging,
microsatellite instability, and loss of heterozygosity on
Chromosome 18q have been used as prognostic factors
for treatment with chemotherapy [10]. Targeted mono-
clonal antibodies against VEGF-A and EGFR have been
approved for therapy of advanced CRC. While resistance
to EGFR antibodies is associated with mutations in the
KRAS gene, an effect of BRAF mutations has not been
proven conclusively [11]. Furthermore, a large propor-
tion of patients with wild-type KRAS do not respond to
EGFR inhibition [12,13]. On the other hand, inhibition
of EGFR has recently been shown to have a synergistic
effect on BRAF(V600E) inhibition [14]. In order to bet-
ter select patients that will respond to targeted treatment
Dry and colleagues employed a pathway-based approach
to derive a gene expression signature predictive of sensi-
tivity to MEK inhibition by assessing activation of MEK
and compensatory signaling from other RAS effectors
[15]. These efforts highlight the importance of gaining a
better understanding of the molecular differences be-
tween CRC subtypes at the pathway level. Since clinical
response data for targeted treatments are very limited,
cell line models have become an increasingly important
tool for research into the molecular basis of different
cancers and linking molecular features to phenotypes
such as drug response [16,17].
A number of studies have been conducted in CRC,
often in a supervised fashion, to develop gene expression
signatures capable of identifying patient populations athigh risk of recurrence [18-26]. In other cases, authors
developed signatures of differentially expressed genes
that allow distinguishing between different tumor stages
[27,28], or normal samples from tumors and metastases
[29-31]. Recently, unsupervised analyses have been con-
ducted with the goal of discovering CRC subtypes and
explain functional differences [32-34]. First, Loboda et al.
described two major CRC subtypes which were shown
to correlate with a signature of epithelial-mesenchymal-
transition [32]. Later, Oh and colleagues applied hierarch-
ical clustering to a CRC patient cohort and identified a
gene signature that was associated with survival and
response to chemotherapy [33]. Perez-Villamil et al. found
four CRC subtypes based on hierarchical clustering in-
cluding a stromal subtype that was associated with poor
survival [34].
In the present study, we set out to discover subtypes
of primary CRC tumors with the aim to better
characterize their functional differences on the pathway
level. In contrast to previous studies, we employed a
new iterative clustering method which allows us to de-
tect expression patterns of varying strength. Instead of
relying on highly variable probe sets, our method
employs randomly selected probe set groups that cover
a large portion of the expression data. As a result, our
method is unbiased with respect to prior knowledge
about certain genes or pathways. Furthermore, we pro-
vide the first alignment of pharmacologically character-
ized cell line panels to the discovered tumor subtypes.
This enables us to assess how well primary tumor sub-
types are covered by available cell line panels. To the
best of our knowledge, we provide the first attempt at
deriving hypotheses about response of individual sub-
types to targeted treatment. First, we identified two
subtypes showing strong association with an EMT
phenotype and significant differences in survival times
and microsatellite status. A subsequent second split of
these two subtypes yielded five subtypes providing a
more fine grained stratification. We demonstrate that
these subtypes can be robustly reproduced on an inde-
pendent set of over 1600 CRC tumor samples drawn
from 15 previously published studies. More importantly,
repeating the subtyping procedure on an independent
dataset resulted in discovery of highly similar subtypes.
By applying the subtyping to 74 different CRC cell lines,
we show that all tumor subtypes are represented in the
cell lines implying that the cell lines largely reflect the
gene expression heterogeneity present in tumors. The
integration of pharmacology data reveals that cell lines
assigned to specific subtypes show exquisite sensitivity
to targeted inhibitors. This provides evidence that the
subtyping can be used for developing and selecting tar-
geted treatments for specific subpopulations of CRC
tumors.
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Tumor and cell line datasets
CRC Tumor data
We performed genome-wide mRNA expression profiling
on 62 primary CRC samples (AZTS, GSE35896, Table 1,
Figure 1) using Affymetrix HGU133plus2 GeneChips
according to the manufacturer's protocol (Affymetrix,
Santa Clara, CA). We also downloaded 15 CRC tumor
sample expression datasets encompassing a total of 1643
samples from the Gene Expression Omnibus all hybri-
dized on the same Affymetrix HGU133plus2 platform
(see Additional file 1: Table S1).CRC cell line data
We analyzed an available dataset consisting of gene ex-
pression profiles of 54 CRC cell lines (AZCL, Chresta
CM et al., in preparation) as well as MSI status and mu-
tation status for KRAS, BRAF, p53, PiK3CA, APC, and
PTEN. We downloaded one cell line gene expression
dataset from the Gene Expression Omnibus (GSE8332
[35]) and data from the GSK Cancer Cell Line panel
from caBIG at the National Cancer Institute (GSK, [36]).
All three cell line panels were hybridized on the
Affymetrix HGU133plus2 platform (see Additional file
1: Table S2). From ArrayExpress, we also downloaded
a dataset containing the gene expression data for 34
large intestine cell lines hybridized on the Affymetrix
HGU133A array (accession number E-MTAB-783 [16]).
This dataset was generated in the Cancer Genome
Project at the Wellcome Trust Sanger Institute and will
be referred to as the ‘Sanger set’.Data analysis
We used R/Bioconductor software [37] for all processing




Age 30 – 39 1
40 – 49 4
50 – 59 8
60 – 69 25
70 – 79 20
80 – 89 4
AJCC stage I/II/III/IV/unknown 0/26/7/1/28
TNM stages T0/T1/T2/T4/TX 0/0/1/30/6/25
N0/N1/N2/NX 8/7/3/44
M0/M1/MX 49/1/12
Microsatellite instability status MSI/MSS/unknown 5/56/1raw intensity values for each dataset independently using
RMA as implemented in the affy package [38]. We
mean-centered expression values for individual probe
sets for determining differential expression, hierarchical
clustering, and plotting heatmaps. We utilized 1 – Pear-
son correlation as distance measure and complete link-
age for hierarchically clustering expression data. To
perform the combined analysis of the sets AZCL, GSK,
and GSE8332, we normalized gene expression data for
these datasets together but mean-centered each set sep-
arately to subtract any batch effect. Data for the cell
lines C10, C125PM, C80, C99, CCK81, DLD1, HCA46,
HRA19, LS513, NCI747, Vaco10MS, Vaco4A, Vaco4S,
and Vaco5 in the AZCL set were treated as separate
batch for mean-centering. We averaged expression
values from cell line replicates within each panel before
assigning them to subtypes. The mapping of probe sets
to ENTREZ gene identifiers, gene symbols, and KEGG
[39] pathways was done using the hgu133plus2.db pack-
age (version 2.7.1). Presence/absence calls for probe sets
were calculated from RMA expression by applying the
PANP package [40]. We utilized the genefilter and the
multtest packages to perform t-tests and Benjamini-
Hochberg multiple testing correction, respectively. We
utilized Fisher’s exact test to detect significant differ-
ences of clinical annotation between subtypes. To
increase statistical power, we combined different data-
sets with the same annotation for this analysis. Samples
contained in both datasets GSE14333 [26] and
GSE17536 [41] were removed from GSE14333 for the
combined analyses. Survival data was available for a
total of 578 tumor samples from the sets GSE17536
[41], GSE17537 [41], GSE14333 [26], GSE33113 [42],
and GSE37892. Staging was available for 488 of these
samples and shows that roughly 75% are classified in
intermediate stages (Additional file 1: Table S3). The
survival time analysis was performed using the survival
package. We censored survival data at follow-up time of
120 months because the number of samples with longer
follow-up was small.
Non-negative matrix factorization (NMF)
We employed the NMF R-package [43] to perform non-
negative matrix factorization (see Additional file 1) and
the iterative NMF (iNMF, Figure 2). With each iteration
of iNMF, sample clusters become more homogeneous in
their expression. Therefore, it is possible to detect more
subtle expression differences and achieve a more
detailed subtyping. By applying NMF to many randomly
selected probe set groups, iNMF achieves a stable sam-
ple clustering to detect so-called core clusters. The
genes that serve as ‘signature’ genes for the subtypes are
significantly differentially expressed between pairs of
core clusters representing the subtypes. As input for
Figure 1 Histology images of four samples from AZTS (20x magnification).
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sion values without mean-centering. We utilized 100
random probe set groups to carry out the iNMF analysis
(see Additional file 1 for details). For each of those
groups, we determined the optimal number of clusters
using the cophenetic correlation coefficient (see Additional
file 1 for details) and chose the most frequently selected
number of clusters. Then, we calculated how often two
samples co-clustered using the 100 random probeFigure 2 Overview of the workflow followed in this work (left) and th
clustering approach (right). (A) First, we clustered a dataset consisting of
(B) Then, we applied iNMF for stratifying the samples with an unbiased sel
resulting clusters. (D) By overlaying matching pharmacology data, (E) we in
response of cell lines in different clusters.set groups. We determined core clusters of samples
(Additional file 1: Table S4) based on a hierarchical
clustering of this matrix but required samples to co-
cluster at least 80 times. To detect differentially
expressed genes, we compared expression of the 5000
genes with the highest variance between two single
core clusters using the t-test and defined probe sets
as differentially expressed if they had a Benjamini-
Hochberg corrected FDR < 0.01. Using these probe sets,e proposed iterative Nonnegative Matrix Factorization (iNMF)
62 CRC samples using NMF based on four selected pathways.
ection of probe sets and (C) matched CRC cell lines (CL) to the
vestigated the potential for generating testable hypotheses regarding
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into the number of clusters determined by iNMF, thereby
assigning the samples to the subtypes represented by these
clusters. The hierarchical clustering agreed fully with the
assignment of samples to core clusters. The resulting sam-
ple clusters were individually used as input set for the
second iteration of the algorithm, following the same steps
as outlined above to define the second level subtypes.INMF expression signatures
We detected 2154 probe sets (1351 genes) and 596 probe
sets (408 genes) to be significantly up-regulated in Types 1
and 2, respectively (Additional file 2: Table S5 and
Additional file 3: Table S6). Subsequently, Type 1 was split
into three subtypes, 1.1, 1.2, and 1.3 that are defined by
up-regulation of 439 probe sets (287 genes) for Subtype
1.1, 193 probe sets (141 genes) for Subtype 1.2, and 352
probe sets (219 genes) for Subtype 1.3 (Additional file 4:
Table S7, Additional file 5: Table S8 and Additional file 6:
Table S9). By further subdividing Type 2, we identified
subtypes 2.1 and 2.2 with gene signatures consisting of
298 probe sets (200 genes) and 304 probe sets (202 genes),
respectively (Additional file 7: Table S10 and Additional
file 8: Table S11).EMT signature
We assembled an EMT expression signature by combi-
ning two published EMT signatures [32,44], with genes
from the SABiosciences EMT PCR array (SABiosciences,
Frederick, MD). We annotated the genes as down- or
up-regulated during EMT according to the source and
removed genes with conflicting expression changes be-
tween different sets. In all cases, gene symbols were
translated to probe set identifiers.Functional analysis
We performed a functional analysis of the subtype signa-
tures using Signaling Pathway Enrichment using Experi-
mental Datasets (SPEED) [45], and enrichment analyses
on the Molecular Signatures Database (MSigDB) [46], and
KEGG [39] and Pathway Interaction Database (PID) [47]
using BioMyn [48]. Briefly, SPEED calculates enrichment
of a gene list with signatures of downstream targets of
selected pathways that were derived from pathway
perturbation experiments. A significant overlap with a sig-
nature of a given pathway suggests that this pathway is
activated. MSigDB contains gene sets divided into five
collections: positional, curated, motif, computational, and
GO; we calculated the overlap between the lists of genes
that are differentially expressed between subtypes to the
gene sets in all but the computational collection.Comparison to published CRC subtype gene expression
signatures
We extracted the expression signatures published by
Loboda et al. [32] and Oh et al. [33] and applied them
to the datasets GSE2109 (provided by the Expression
Project for Oncology of the International Genomics
Consortium), GSE14333, GSE17536, and GSE17537. To
this end, we calculated for each sample the difference
between mean expression of the mesenchymal signature
and the epithelial signature defined by Loboda and col-
leagues. Also, we subtracted for each sample the mean
expression of genes up-regulated in type A from the
mean expression of genes up-regulated in type B as
defined by Oh and colleagues. Additionally, we deter-
mined expression of genes contained in the stromal sig-
nature published by Perez-Villamil et al. [34].Drug treatment
For measuring drug response in the AZCL panel, cell
lines were maintained in the logarithmic phase of
growth. The anti-proliferative activity of compounds was
measured as EC50 values at 72 h after drug dosing using
the MTS tetrazolium dye method (Promega), prolifera-
tion assays were seeded at appropriate density to ensure
logarithmic growth during the 72 h dosing period. For
each compound, the mean -log10 (EC50) was computed
across all cell lines and subtracted from -log10 (EC50)
value for each cell line. The resulting value is positive if
a cell line is more sensitive to treatment with this com-
pound than the average over all lines and negative if it is
more resistant. For the Sanger cell line panel, we down-
loaded IC50 values provided by the Cancer Genome
Project group at the Wellcome Trust Sanger Institute
from http://www.cancerrxgene.org/translation/Drug on
June 6, 2012 [16]. As for the AZCL set, we calculated
the average -loge(IC50) for each compound across all
cell lines and subtracted this value from -loge (IC50) for
each cell line. The resulting value is positive if a cell line
is more sensitive than average to treatment with a spe-
cific compound.Results
Five CRC subtypes are revealed by iterative clustering
For a pathway-based stratification of CRC tumor samples,
we selected four pathways known to play a role in progres-
sion of CRC: MAPK signaling (KEGG: hsa04010), mTOR
signaling (KEGG: hsa04150), ErbB signaling (KEGG:
hsa04012), and colorectal cancer disease pathway (CRCdp,
KEGG: hsa05210). Applying NMF independently to the
gene sets annotated to these four pathways resulted in two
sample clusters that were overlapping significantly for the
ErbB, MAPK, and CRCdp pathways, indicating dominant
gene expression differences involving these pathways.
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domly selected groups of probe sets, roughly equal in
size to these pathways. See Figure 2 for a schematic rep-
resentation of the iNMF procedure. The first iteration of
iNMF resulted in two sample clusters (Types 1 and 2).
In the second iteration, Type 1 was split into three sub-
types, denoted as Subtypes 1.1, 1.2, and 1.3, whilst appli-
cation of iNMF to Type 2 led to the identification of
Subtypes 2.1 and 2.2 (Table 2 and Figure 3). The gene
signatures are listed in Additional file 2: Table S5,
Additional file 3: Table S6, Additional file 4: Table S7,
Additional file 5: Table S8, Additional file 6: Table S9,
Additional file 7: Table S10, Additional file 8: Table S11
for the respective subtypes. When we applied iNMF to
10.000 additional randomly selected probe set groups,
the core clusters did not change significantly showing
that the discovered subtypes do not depend on the ran-
domly selected probe set groups.
The CRC subtypes are present in independent datasets
In order to further establish the robustness of the
iNMF method and the resulting stratification, we per-
formed two rounds of validation. First, we hierarchic-
ally clustered several independent, publically availableTable 2 Comparison of clinical and molecular characteristics o
iNMF step 1
Molecular feature Type 1
No. of tumor samples (AZTS) 28
No. of tumor samples (all datasets) 944
EMT expression signature mesenchymal
Survival prognosis poor
Microsatellite status similar number of MSI and MSS
iNMF step 2
Molecular feature Subtype 1.1 Su
No. of tumor samples (AZTS) 12 9
No. of tumor samples (all datasets) 313 30
Average percent tumor foci area 79.2 81
Average percent tumor cells in foci 76.3 74
Average percent stromal cells in foci 18.3 18
Average percent inflammatory cells in foci 3.8 7.
EMT expression signature strongly mesenchymal m
Tumor location colon/left/rectum/right 0/26/16/15 1/
Microsatellite status MSI/MSS 14/15 42
Tumor stage enriched in late stage CRC
Gender enrichment Female/Male/Unknown 87/99/0 89




Differences in these characteristics were assessed using all datasets with available aCRC expression datasets totaling 1643 samples
(Additional file 1: Table S1) with the probe sets that
were found to be differentially expressed between
subtypes in our dataset. Additional file 9: Table S12
summarizes the results. Figure 3 depicts an overview
of the expression signatures across the biggest
datasets. It is clear that we were able to identify all
subtypes in external datasets. More importantly, the
expression of the signature genes is consistent across
the different datasets.
Second, we applied iNMF to a large independent
set GSE14333 (n = 290) and investigated the overlap
of the resulting stratification with the one obtained
from the first validation. We utilized the same groups
of randomly selected probe sets and performed two
iterations of iNMF. The first iteration identified very
similar CRC Types 1 and 2 as before (Fisher exact p-value
< 2.2*10-16), and 68% and 71% (p-values < 9.9*10-16) of the
genes that were previously found to be up-regulated in
CRC Types 1 and 2, respectively. The subtypes identified
in the second iteration were also significantly similar
(simulated Fisher exact p-value = 5*10-4). The overlaps of
gene signatures were significant for subtypes of Type 1






CRC enriched with MSS CRC
btype 1.2 Subtype 1.3 Subtype 2.1 Subtype 2.2
7 14 20
3 328 313 449
.4 77.9 82.1 79.7
.5 80.0 73,8 73.7
.3 12.2 21.2 21.2
2 6.4 3.5 4.7
esenchymal mesenchymal epithelial epithelial
12/1/29 0/12/2/11 1/22/9/37 1/50/11/33
/9 2/35 27/31 4/50






cell cycle and amino




Figure 3 Expression patterns of CRC subtypes defined by iNMF in different datasets: (A) Types 1 (black) and 2 (green) from iNMF
iteration 1; (B) Subtypes 1.1, 1.2, and 1.3; and (C) Subtypes 2.1 and 2.2. Samples are shown in columns and probe sets contained in the
subtype signatures are shown in rows.
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clinical characteristics
To gain insight into the correlation of the iNMF stratifi-
cation with available clinical annotation, we made use of
the annotation available for some datasets. Here, it has
to be noted that clinical annotation varies substantially
between different datasets. Table 2 summarizes the dif-
ferences in clinical characteristics.
Survival analysis revealed that Type 1 had significantly
worse disease free survival (p-value = 9*10-3) than Type
2 (Additional file 1: Figure S1). Using survival and
chemotherapy annotation of samples in GSE14333, an
univariate Cox regression model indicated that Stage C
tumors assigned to Type 1 had a significantly improved
disease free survival if treated with chemotherapy
(p-value = 0.04) while Stage C tumors in Type 2 did not
show such a benefit. Furthermore, there was also a sig-
nificant difference in the distribution of MSI samples
(p-values < 8.68*10-4) between Subtypes 1.1, 1.2 and 1.3.The three subtypes of Type 1 also showed significant
differences in terms of distribution of tumor location
(p-value = 3.42*10-3). Of note, there was also a significant
difference in distribution of male and female samples
(p-value = 1.12*10-3) with Subtype 1.2 being the only
subtype comprising more tumors of female than male
patients.Major CRC types exhibit a mesenchymal and an epithelial,
cell cycle-activated profile
To further characterize the CRC subtypes at a functional
level, we subjected the lists of subtype signature genes to
a functional analysis using Signaling Pathway Enrich-
ment using Experimental Datasets (SPEED) [45], the
Molecular Signatures Database (MSigDB) [46], and
KEGG [39] and Pathway Interaction Database (PID) [47]
using BioMyn [48]. A detailed description of the results
can be found in Additional file 1.
Figure 4 Overview of SPEED analysis of pathway activation in (A) Types 1 and 2, (B) Subtypes 1.1, 1.2, and 1.3, and (C) Subtypes 2.1
and 2.2. The y-axes denote negative logarithm to base 10 of the activation p-value. The horizontal lines indicate the significance threshold of
p-value = 0.05.
Schlicker et al. BMC Medical Genomics 2012, 5:66 Page 8 of 15
http://www.biomedcentral.com/1755-8794/5/66
Schlicker et al. BMC Medical Genomics 2012, 5:66 Page 9 of 15
http://www.biomedcentral.com/1755-8794/5/66For Type 1, we found a large number of pathways to be
activated, which are related to inflammation, angiogenesis,
extracellular matrix, proliferation, and differentiation
(Figure 4A). In contrast, Type 2 can be characterized by
activation of the Wnt pathway, up-regulation of cell cycle-
related genes, including aurora kinase A. Since a number
of pathways that have been linked to EMTare significantly
more activated in Type 1, we performed a hierarchical
clustering of the AZTS dataset using an EMT-related gene
signature. This revealed a high concordance between
stratification into Type 1 and 2 and mesenchymal and epi-
thelial expression profiles (Additional file 1: Figure S2),
respectively (Chi square p-value = 4.7*10-10). These results
confirm previous evidence [32] that EMT is correlated
with dominant expression changes in CRC.
Subtypes show selective pathway activation
We also identified several pathways to be activated in
the subtypes. Subtype 1.1 is characterized by pathways
involved in angiogenesis, inflammation, and proliferation
(Figure 4B). Intriguingly, we also found a significant up-
regulation of the calcium signaling KEGG pathwayFigure 5 Comparison between iNMF subtypes and subtypes identifie
GSE2109, GSE14333, GSE17536, and GSE17537. The x- and y-axes depict the
Oh et al. and Loboda et al. Lines along the axes represent the density of sa(p-value = 0.01) in 1.1. Subtype 1.2 shares activation of
many pathways with Subtype 1.1 but strong activation of
JAK-STAT is unique to 1.2 (Figure 4B). In Subtype 1.3,
we identified genes annotated with several Gene Ontology
(GO) [49] terms related to transport across membranes
(p-values < 0.05) to be up-regulated (Table 2).
In Subtype 2.1, we identified several activated pathways
related to inflammation, angiogenesis, and proliferation
(Figure 4C). Intriguingly, we identified a number of genes
to be up-regulated in Subtype 2.2 from two cytogenetic
bands on the q-arm of Chromosome 20 (20q11 and 20q13,
p-values < 5.68*10-5), and several bands on Chromosome
13q (13q13-14, 13q32-34, p-values < 3.96*10-2).
Comparison with published subtype signatures
Recently, Loboda et al. showed that EMT represents a
dominant gene expression signal in human CRC [32].
The mesenchymal and epithelial subtypes identified by
Loboda and colleagues largely agree with the dominant
iNMF Type 1 and 2. Oh et al. identified two subtypes
that exhibit differences in survival and response to
chemotherapy [33]. As shown in Figure 5, the twod by Loboda et al. and Oh et al. Shown are samples contained in
difference between average expression of signatures published by
mples of the respective iNMF subtypes.
Schlicker et al. BMC Medical Genomics 2012, 5:66 Page 10 of 15
http://www.biomedcentral.com/1755-8794/5/66published signatures clearly detect different tumor sam-
ples and features of CRC. The iNMF subtyping reveals the
extremes of these groups, high expression of both signa-
tures, is associated with Subtype 1.1, whilst low expression
of both signatures correlates with Subtype 2.2. In addition,
the iNMF subtying combines the features of the two signa-
tures to further discriminate CRC subtypes, e.g. Subtype 2.1
is epithelial with either low or high expression of the Oh
type B signature. Recently, Perez-Villamil et al. identified
four subtypes in CRC including a stromal, poor survival
subtype. As shown in Additional file 1: Figure S3, genes in
this stromal signature are mainly expressed in Type 1 sam-
ples indicating that the stromal signature cannot distinguish
between the detailed subtypes identified by iNMF.
CRC cell line panels represent all five subtypes
In order to assess how well the identified CRC subtypes
are represented in available cell line panels, weFigure 6 Expression patterns of CRC subtypes defined by iNMF in the
matched to Types 1 (black) and 2 (green) show a very similar expression p
subtypes of Type 1 and (C) subtypes of Type 2 shows less similarity with exinvestigated four different datasets. First, we applied the
subtype signatures obtained by iNMF using hierarchical
clustering to a diverse, combined panel containing 67
CRC cell lines (AZCL, GSK, GSE8332). In general, the
expression of signature genes in cell lines was less pro-
nounced, but nevertheless, all subtypes were identified
(Figure 6 and Additional file 1: Table S13). Furthermore,
the alignment of cell lines to subtypes was consistent
across datasets, SW480 being the only cell line showing
inconsistent alignment. In general, we observed that the
expression of genes pointing at activation of specific
pathways in the SPEED analyses is less consistent in cell
lines than in tumor samples. The genes indicating acti-
vation of Jak-Stat signaling in tumors in Subtypes 1.2
and 2.1, for instance, are not consistently expressed in
the cell lines assigned to these subtypes. However, the
average expression of all genes in the SPEED Jak-Stat
signature is significantly higher in 1.2 cell lines than in 1.1AZTS set and different cell line panels. (A) Cell lines that are
attern to the tumor samples. Expression in cell lines assigned to (B) the
pression in tumor samples.
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dicating that the pathway activation may be conserved be-
tween primary tumors and cell lines in the same subtype.
Furthermore, expression of EMT markers in cell lines
shows a similar pattern as in tumor samples (Additional
file 1: Figure S4).
Last, we applied the subtype signatures to the Sanger
dataset, comprising 34 cell lines that were profiled on a
different expression platform (Additional file 1: Table
S14). The stratification of cell lines overlapping between
the Sanger set and the other cell line panels was highly
similar (p-value = 8.6*10-6).
Differential response of CRC subtypes to targeted
inhibitors
To assess the potential clinical utility of the subtypes, we
determined whether cell lines assigned to different sub-
types respond differently to targeted inhibitors. To this
end we determined the association between pharmaco-
logical response data available for part of the AZCL set
(Figure 7, Additional file 10: Table S15) and the Sanger
set with the subtyping (Figure 8, Additional file 1: Table
S16). These two independent datasets overlap partly in
terms of cell lines. In both cases, we pooled compounds
with the same target for this analysis.
Aurora kinase A was one of the genes significantly up-
regulated in Type 2. In accordance with this, cell lines
assigned to Type 2 are significantly more sensitive to
treatment with targeted aurora kinase inhibitors thanFigure 7 Pharmacological response of cell lines in the AZCL panel to
average –log10 (EC50) of cell lines assigned to one subtype and average –l
indicated protein. Positive or negative values indicate that cell lines in a clu
average. Standard error of subtype means are represented as lines.cell lines of Type 1 (p-value = 1.9*10-3). Furthermore, cell
lines assigned to Subtype 1.2 show a specifically high
sensitivity to treatment with inhibitors of glycogen syn-
thase kinase, the proto-oncogene tyrosine-protein kinase
Src, and Wnt-signaling.
The analysis of the Sanger pharmacology data provides
further validation for the high sensitivity of Subtype 1.2
cell lines to targeted inhibition of Src. As for the AZCL
dataset, cell lines assigned to 1.2 exhibit the highest
average sensitivity to these compounds.
Discussion
In this work, we introduced iterative nonnegative matrix
factorization based on randomly selected probe sets and
applied it for stratifying CRC samples in a two-step
process into two main types and subsequently into five
subtypes. In contrast to previous studies, this iterative
process enables us to detect a hierarchical relationship
between subtypes based on expression differences of
varying strength. Being based on randomly selected
probe sets, iNMF has the advantage that it is unbiased
with respect to knowledge about genes and pathways.
The subtype signatures consisting of differentially
expressed probe sets can be easily applied for hierarchic-
ally clustering independent CRC datasets in a two step
process, thereby assigning the samples to their respective
subtypes.
The presented CRC stratification was validated by clus-
tering independent CRC expression datasets using thetargeted inhibition. The y-axis denotes difference between
og10 (EC50) of all measurements for compounds targeting the
ster are more sensitive or resistant, respectively, than the overall
Figure 8 Pharmacological response of cell lines in the Sanger panel to targeted inhibition. The y-axis denotes difference between average
–log10 (IC50) of cell lines assigned to one subtype and average –log10 (IC50) of all measurements for compounds targeting the indicated protein.
Positive or negative values indicate that cell lines in a cluster are more sensitive or resistant, respectively, than the overall average. Standard error
of subtype means are represented as lines.
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to an independent dataset, which resulted in highly similar
subtypings. These results prove that our method and
stratification are robust and transferable to other datasets,
and that the lists of differentially expressed probe sets are
applicable for the stratification of independent expression
datasets and robust against confounding factors typically
present in independent datasets.
The functional analyses of differentially expressed probe
sets provided insight into differences in the activation of
key signaling pathways in distinct types and subtypes and
interesting start points for further investigations. The first
iteration revealed a mesenchymal (Type 1) and a highly
proliferative, epithelial (Type 2) type. This difference be-
tween epithelial and mesenchymal types is not correlated
to the amount of infiltration by stromal cells as tumor
sampels in all subtypes show similar percent stromal cells
(Table 2). Further stratifying the mesenchymal type identi-
fied a subtype with signs of activation of MAPK, TGFβ,
and calcium signaling (Subtype 1.1), a subtype with activa-
tion of immune system-related pathways (Subtype 1.2),
and one with high expression of transporter genes (Sub-
type 1.3). The subdivision of the epithelial type revealed a
subtype showing activation of immune system-related
pathways (Subtype 2.1), and a subtype with high expres-
sion of genes on chromosomes 13q and 20q (Subtype 2.2).
Many of the pathways identified here as activated in
specific subtypes were also shown to be targeted byrecurrent alterations in a recent analysis by The Cancer
Genome Atlas Network [50]. In this analysis, most sam-
ples were found to harbor alterations leading to an acti-
vation of WNT signaling which is in agreement with the
finding that WNT is the only pathway analyzed that
seems to be activated in both Types 1 and 2. Further-
more, receptor tyrosine kinase-RAS signaling was
affected in a substantial number of tumors, and we iden-
tified classical MAPK signaling to be activated in Type 1
and specifically in Subtype 1.1. Recently, Seshagiri and
colleagues analyzed next-generation sequencing data
obtained from 70 primary human colon tumors [51] and
found frequent mutations in 356 candidate CRC genes
previously identified in screens in mouse models of CRC
[52,53]. More than 8% of these genes are also contained
in the signatures associated with the iNMF subtypes pre-
sented here. Clusterin, for example, is highly expressed
in Type 1 and known to regulate NF-κB activity [54] and
inhibit apoptosis [55]. Type 2 tumors, on the other hand,
show high expression of dachshund homolog 1 which
inhibits TGFβ signaling through binding to SMAD4 [56]
and possibly contributes to the difference in TGFβ
signaling between Type 1 and 2. This provides further
evidence that the iNMF signatures and the differences in
pathway activation between subtypes represent CRC intrin-
sic features and contribute to their better understanding.
Subtype 1.2 is highly enriched for tumors showing MSI,
which have been shown to have substantial amounts of
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percent of infiltrating inflammatory cells is comparable
across subtypes (Table 2), Subtype 1.2 indeed shows the
highest average and this might have influenced the gene
expression signatures. Unexpectedly, Subtype 1.2 is the
only subtype that comprises more female than male
tumors. Previously, it has been reported that there are dif-
ferences regarding the location distribution of colorectal
tumors between the genders, e.g. that in women right-
sided CRC is more common [58] and that pathological
and molecular features of the tumors vary between loca-
tions [59]. These variations might cause changes in gene
expression which are detected by iNMF.
Aligning cell lines with tumor samples to enhance
their utility as pre-clinical predictive models has proved
challenging for many tumor types. We observed that
the four cell line panels investigated here generally pro-
vided a good coverage of the space of primary tumor
samples, in contrast to a study by Auman and McLeod
[60]. Although the expression of the signature genes is
less consistent in cell lines, replicates from different
panels were stratified in a highly consistent fashion.
Furthermore, specific biological characteristics agreed
between tumor samples and cell lines assigned to the
same subtype. The observation that expression patterns
for the pathways investigated are not well conserved
between cell lines and tumor samples might indicate
that canonical pathways do not fully reflect mechanistic
complexity. Furthermore, the non-natural culture con-
ditions of cell lines might have an effect on gene ex-
pression which might change the activation of pathways
or the respective expression signal that can be detected.
However, the successful alignment of CRC cell lines to
the newly identified disease subtypes using the techni-
ques described here reveals that the gene expression
profiles which define subtypes remain significantly in-
tact despite extended growth in vitro.
Analysis of two cell line datasets with treatment re-
sponse data indicated that subtypes respond differently to
targeted compounds. Type 2 cell lines are more sensitive
to treatment with aurora kinase inhibitors. This is in
agreement with the high expression of aurora kinase A in
Type 2 tumor samples and suggests that genes included in
the signatures might be good candidates for targeted
treatment of specific CRC subpopulations. Additionally,
pharmacological data for two independent cell line panels
suggests that Subtype 1.2 cell lines are most sensitive to
inhibition of Src. These are interesting hypotheses for the
treatment of the different CRC subtypes that warrant fur-
ther investigation.
The comparison to published signatures showed that
the five iNMF subtypes are neither detected by any of the
existing signatures alone nor by their combination. For
example, most tumors in Subtype 1.2 and many tumors in2.1 have a high Oh B signature but differ in EMT status.
Interestingly, Subtype 1.2 shows a significantly higher sen-
sitivity than Subtype 2.1 to inhibition of proteins on the
PI3K pathway, GSK3β, PI3K, and TOR. This suggests that
the subtyping presented here allows a more fine grained
subdivision of CRC samples which is likely to have greater
utility at linking molecular features to pharmacology.
Conclusions
In summary, we have used tumor gene expression pro-
files to identify new CRC subtypes and have defined
their main pathway differences. Using a large number of
independent datasets, we showed that the stratification
is stable across different datasets, regardless of which
dataset is employed to derive the gene sets with which
to perform the stratification. iNMF is robust with
respect to the starting dataset and can be applied to
identify inherent disease subtypes. Furthermore, we have
presented evidence that CRC cell line panels represent
the different disease subtypes, and that the integration of
pharmacology data offers new opportunities for develo-
ping improved CRC therapies targeted at the new CRC
molecular subtypes and generating clinically tractable
hypotheses for response prediction.
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